Theophylline Pharmacokinetics and Liver Function Indexes in Chronic Liver Disease

Respiration ◽  
1991 ◽  
Vol 58 (2) ◽  
pp. 106-111 ◽  
Author(s):  
P. Amodio ◽  
S. Lauro ◽  
M. Rondana ◽  
G. Crema ◽  
C. Merkel ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Chronic Liver

scholarly journals TOLAK UKUR FUNGSI HATI BERDASARKAN DERAJAT FIBROSIS PENYAKIT HATI KRONIS (Liver Function Parameters based on Degree of Liver Fibrosis in Chronic Liver Disease)

2018 ◽  
Vol 21 (1) ◽  
pp. 57
Author(s):  
Rahmafitria Rahmafitria ◽  
Mutmainnah Mutmainnah ◽  
Ibrahim Abdul Samad
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Total Bilirubin ◽  
Chronic Liver ◽  
Low Degree ◽  
Significant Difference ◽  
The Mean ◽  
High Degree

Evaluating the degree of liver fibrosis degree is invasive as well as uncomfortable, therefore, non invasive examinations such as liverfunction tests and elastography (Fibro Scan) as a predictor‘s device of liver fibrosis degree are necessary. The aim of this study was toknow the differences of liver function parameters based on the fibrosis degree in patients with chronic liver disease. This study was a crosssectional design using data from chronic liver disease patients treated at the Dr. Wahidin Sudirohusodo Hospital. The elasticity of the liverwas measured using a fibro scan device during June 2010–July 2011. The analysis was carried out by ANOVA test on various parametersof liver function particularly on the fibrosis degree in chronic liver disease. In this study PT, albumin, total bilirubin and platelet countshowed a significant difference of 0.019, 0.009, 0.017 and 0.000 respectively. The mean values of PT and total bilirubin were significantlyhigher in the high degree of fibrosis compared to those with medium and low degree of fibrosis in the chronic liver disease patients. Basedon this study, the mean albumin levels and platelet count were significantly lower in the high degree of fibrosis compared with the mediumand low degree of fibrosis, however, no significant differences in AST, ALT, APTT and GGT were found.

scholarly journals Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Qing-Lei Zeng ◽  
Zu-Jiang Yu ◽  
Fanpu Ji ◽  
Guang-Ming Li ◽  
Guo-Fan Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Gamma Glutamyl Transferase ◽  
Dynamic Changes ◽  
Viral Shedding ◽  
Glutamyl Transferase ◽  
Multicentre Retrospective Study

Abstract Background Liver injuries have been reported in patients with coronavirus disease 2019 (COVID-19). This study aimed to investigate the clinical role played by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods In this multicentre, retrospective study, the parameters of liver function tests in COVID-19 inpatients were compared between various time-points in reference to SARS-CoV-2 shedding, and 3 to 7 days before the first detection of viral shedding was regarded as the reference baseline. Results In total, 70 COVID-19 inpatients were enrolled. Twenty-two (31.4%) patients had a self-medication history after illness. At baseline, 10 (14.3%), 7 (10%), 9 (12.9%), 2 (2.9%), 15 (21.4%), and 4 (5.7%) patients already had abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, and total bilirubin (TBIL) values, respectively. ALT and AST abnormal rates and levels did not show any significant dynamic changes during the full period of viral shedding (all p > 0.05). The GGT abnormal rate (p = 0.008) and level (p = 0.033) significantly increased on day 10 of viral shedding. Meanwhile, no simultaneous significant increases in abnormal ALP rates and levels were observed. TBIL abnormal rates and levels significantly increased on days 1 and 5 of viral shedding (all p < 0.05). Albumin abnormal decrease rates increased, and levels decreased consistently from baseline to SARS-CoV-2 clearance day (all p < 0.05). Thirteen (18.6%) patients had chronic liver disease, two of whom died. The ALT and AST abnormal rates and levels did not increase in patients with chronic liver disease during SARS-CoV-2 shedding. Conclusions SARS-CoV-2 does not directly lead to elevations in ALT and AST but may result in elevations in GGT and TBIL; albumin decreased extraordinarily even when SARS-CoV-2 shedding ended.

scholarly journals Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease

2016 ◽  
Vol 47 (3) ◽  
pp. E22-E34 ◽  
Author(s):  
Shunji Koya ◽  
Takumi Kawaguchi ◽  
Ryuki Hashida ◽  
Emiko Goto ◽  
Hiroo Matsuse ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Muscle Mass ◽  
Chronic Liver ◽  
Physical Ability

scholarly journals Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease

2013 ◽  
Vol 305 (5) ◽  
pp. G364-G374 ◽  
Author(s):  
Rana L. Smalling ◽  
Don A. Delker ◽  
Yuxia Zhang ◽  
Natalia Nieto ◽  
Michael S. Mcguiness ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Nuclear Receptor ◽  
Liver Diseases ◽  
Human Liver ◽  
Chronic Liver ◽  
Rna Seq ◽  
Gene Signatures

The molecular mechanisms behind human liver disease progression to cirrhosis remain elusive. Nuclear receptor small heterodimer partner (SHP/ Nr0b2) is a hepatic tumor suppressor and a critical regulator of liver function. SHP expression is diminished in human cirrhotic livers, suggesting a regulatory role in human liver diseases. The goal of this study was to identify novel SHP-regulated genes that are involved in the development and progression of chronic liver disease. To achieve this, we conducted the first comprehensive RNA sequencing (RNA-seq) analysis of Shp−/− mice, compared the results with human hepatitis C cirrhosis RNA-seq and nonalcoholic steatohepatitis (NASH) microarray datasets, and verified novel results in human liver biospecimens. This approach revealed new gene signatures associated with chronic liver disease and regulated by SHP. Several genes were selected for validation of physiological relevance based on their marked upregulation, novelty with regard to liver function, and involvement in gene pathways related to liver disease. These genes include peptidoglycan recognition protein 2, dual specific phosphatase-4, tetraspanin 4, thrombospondin 1, and SPARC-related modular calcium binding protein-2, which were validated by qPCR analysis of 126 human liver specimens, including steatosis, fibrosis, and NASH, alcohol and hepatitis C cirrhosis, and in mouse models of liver inflammation and injury. This RNA-seq analysis identifies new genes that are regulated by the nuclear receptor SHP and implicated in the molecular pathogenesis of human chronic liver diseases. The results provide valuable transcriptome information for characterizing mechanisms of these diseases.

Echo-doppler hepatic measurements combined with quantitative liver function tests in chronic liver disease

2000 ◽  
Vol 32 ◽  
pp. 223
Author(s):  
A. Fasoli ◽  
P. Borro ◽  
F. Botta ◽  
B. Chiarbonello ◽  
P. Durando ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Liver Function Tests ◽  
Chronic Liver ◽  
Function Tests

scholarly journals Management of liver complications in sickle cell disease

Hematology ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 345-350 ◽  
Author(s):  
Abid R. Suddle
Keyword(s):  
Liver Disease ◽  
Sickle Cell Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Sickle Cell ◽  
Clinical Presentation ◽  
Chronic Liver ◽  
Initial Assessment ◽  
Cell Disease ◽  
Surgical Interventions

Abstract Liver disease is an important cause of morbidity and mortality in patients with sickle cell disease (SCD). Despite this, the natural history of liver disease is not well characterized and the evidence basis for specific therapeutic intervention is not robust. The spectrum of clinical liver disease encountered includes asymptomatic abnormalities of liver function; acute deteriorations in liver function, sometimes with a dramatic clinical phenotype; and decompensated chronic liver disease. In this paper, the pathophysiology and clinical presentation of patients with acute and chronic liver disease will be outlined. Advice will be given regarding initial assessment and investigation. The evidence for specific medical and surgical interventions will be reviewed, and management recommendations made for each specific clinical presentation. The potential role for liver transplantation will be considered in detail.

Detecting chronic liver disease: are liver function tests the solution?

2020 ◽  
Vol 81 (2) ◽  
pp. 1-8
Author(s):  
Prarthana Thiagarajan ◽  
Jane Chalmers ◽  
Indra N Guha ◽  
Martin W James
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Liver Function Tests ◽  
Chronic Liver ◽  
Alcoholic Fatty Liver ◽  
Non Invasive ◽  
Function Tests ◽  
Life Years ◽  
The Uk

By 2020, chronic liver disease will have eclipsed ischaemic heart disease as the leading cause of working life years lost in the UK. As mortality from chronic liver disease continues to rise, the landscape of aetiology has shifted from infectious to non-communicable causes. In parallel with the growing prevalence of obesity and type 2 diabetes, non-alcoholic fatty liver disease is estimated to affect 25% of the UK adult population. Simultaneously, escalating alcohol consumption has fuelled public health and economic concerns regarding its widespread impact on working-age adults. Given that chronic liver disease remains clinically silent until its advanced stages, there is an urgent unmet need to identify affected individuals earlier in the disease process, enabling targeted intervention strategies which may improve prognosis. Robust epidemiological data have shown that liver fibrosis is the strongest predictor of clinically meaningful outcomes, including decompensation, liver cancer and overall mortality. Detecting fibrosis among at-risk individuals, in a manner that is reproducible, non-invasive, safe and cost effective, has become a major challenge of our time. This article addresses the pitfalls of the standard panel of liver function tests, discusses other non-invasive biomarkers and reviews imaging technologies which may revolutionise community-based diagnosis and stratification of chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document